Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil
HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab. Chembio’s delivery of the full number of tests covered by the purchase order may be affected by limitations of Chembio’s supply chain, staffing, and liquidity, and other matters outside Chembio’s control.
Akoya to Report Second Quarter 2021 Financial Results on August 10, 2021
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Akoya Announces Publication of the MITRE Study, the First
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Silk Road Medical to Report Second Quarter 2021 Financial Results on July 29, 2021
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share:
MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world s most prevalent eye diseases, today announced the pricing of its initial public offering of 10,000,000 shares of common stock at a public offering price of $24.00 per share. All shares of common stock are being offered by Sight Sciences for total gross proceeds of $240 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Sight Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Sight Sciences s common stock is expected to begin trading on the Nasdaq Global Market on July 15, 2021, under the ticker symbol SGHT. The offering is expected to close on Ju